| Samarth Kulkarni |
Samarth Kulkarni is currently the Chairman & Chief Executive Officer at CRISPR Therapeutics AG. He is also the Chief Executive Officer at CRISPR Therapeutics, Inc. Additionally, he holds the position of Director-Emerging Companies Section at Biotechnology Innovation Organization. Dr. Kulkarni is the Lead Independent Director at Black Diamond Therapeutics, Inc. and an Independent Director at Repare Therapeutics, Inc. He is also an Independent Non-Executive Director at Centessa Pharmaceuticals Plc. In the past, Dr. Kulkarni served as the Chairman at Casebia Therapeutics LLP and as a Director at Casebia Therapeutics LLC. Prior to that, he was a Partner at McKinsey & Co., Inc. from 2006 to 2015. Dr. Kulkarni holds a doctorate degree from the University of Washington and an undergraduate degree from the Indian Institute of Technology New Delhi. |
| Phuong Khanh Morrow |
Presently, Phuong Khanh Morrow occupies the position of Chief Medical Officer at CRISPR Therapeutics AG.
In the past she was Vice President for Amgen Switzerland AG and Assistant Professor at The University of Texas M.D. Anderson Cancer Center.
She received a doctorate from Dell Medical School and an undergraduate degree from the University of Houston. |
| Raju Prasad |
Raju Prasad is currently the Chief Financial & Accounting Officer at CRISPR Therapeutics AG since 2023. Prior to this, he worked as a Research Analyst at William Blair & Co. LLC from 2014 to 2023. Dr. Prasad completed his undergraduate degree at Rutgers State University of New Jersey, his graduate degree at the University of Delaware, and his doctorate at The University of North Carolina at Charlotte. |
| Jonathan Alexander Terrett |
Jonathan Alexander Terrett is currently the Head of Research at CRISPR Therapeutics AG. He previously worked as a Director at Medarex, Inc., Director at Oxford BioTherapeutics Ltd., Director at Oxford GlycoSciences Plc, Director at Celltech R&D Ltd., Principal at Smithkline Beecham Plc, and Vice President of Oncology Discovery at CytomX Therapeutics Holdings LLC. He obtained his undergraduate degree from The University of Sheffield and his doctorate degree from The University of Nottingham in 1996. |
| Stephen R. Kennedy |
Stephen R. Kennedy is currently the Head-Technical Operations at CRISPR Therapeutics AG. Previously, he held positions as an Executive Director at Novartis, Inc., an Executive Director-MIT Center at Massachusetts Institute of Technology, a Director at Sweet Natural Trading Co. Ltd., a Principal at Eastman Kodak Co., a Principal at Genencor International, Inc., a Senior VP-Biologics Technical Operations at Genzyme Corp., an Executive Vice President-Research & Development at Mascoma Corp., and the Chief Operating Officer & Executive Vice President at Histogenics Corp. He also served as the Senior Vice President & Head-Technical Operations at Casebia Therapeutics LLC. Mr. Kennedy obtained a graduate degree from Rochester Christian University, an MBA from Boston University, and an undergraduate degree from the University of Michigan. |
| Maria Fardis |
Maria Fardis is currently the Chief Executive Officer at Lassen Therapeutics LLC since 2023. She is also the Chairman at Obsidian Therapeutics, Inc. since 2021. Additionally, Maria serves as an Independent Director at CRISPR Therapeutics AG. She holds director positions at Quanta Therapeutics, Inc. and Kartos Therapeutics, Inc. Maria is a Venture Partner at Frazier Management LLC since 2021. In her former roles, Dr. Fardis served as the President, Chief Executive Officer & Director at Iovance Biotherapeutics, Inc. from 2016 to 2021. She was an Associate Director-Project & Portfolio Management at Gilead Sciences, Inc. in 2012. Maria also held positions as the Chief Oncology Operations & Alliances at Pharmacyclics LLC from 2013 to 2014 and as the Chief Operating Officer at Acerta Pharma BV. She later became the Chief Operating Officer at Acerta Pharma LLC from 2015 to 2016. Dr. Fardis has also served as a Director at the Alliance for Regenerative Medicine. Dr. Fardis holds an MBA from Golden Gate University. She obtained a doctorate degree from the University of California, Berkeley and an undergraduate degree from the University of Illinois At Urbana–Champaign. |
| Katherine A. High |
Katherine A. High was the founder of Spark Therapeutics, Inc. founded in 2013, where she held the title of President, Head-Research & Development. Currently, she holds the position of Independent Director at Incyte Corp. and CRISPR Therapeutics AG. She is also a Director at Virion Therapeutics LLC and Innovative Genomics Institute. In the past, she held the position of Director & President-Therapeutics at Asklepios BioPharmaceutical, Inc. from 2021 to 2022. She was the Director of the Center for Cellular at The Children's Hospital of Philadelphia from 2004 to 2014 and a Professor at Perelman School of Medicine from 1999 to 2014. She also served as the President of the American Society of Gene & Cell Therapy. Dr. High received her undergraduate degree from Harvard University, her graduate degree from the University of Pennsylvania, and her doctorate from UNC School of Medicine. |
| John T. Greene |
John T. Greene is currently an Independent Director at CRISPR Therapeutics AG and the Chief Financial Officer & Executive Vice President at Discover Financial Services. Previously, he held the position of Chief Financial Officer-Global Business Finance at GE Aerospace from 1993 to 2005. He also served as the Chief Financial Officer at HSBC Holdings Plc and HSBC Insurance Co. of Delaware. From 2014 to 2016, he was the Group Chief Financial Officer at Willis Group Holdings Plc. Additionally, he worked as the CFO-Retail Bank & Wealth Management at HongKong & Shanghai Banking Corp. (New York) from 2009 to 2014. From 2016 to 2018, he held the role of CFO, Treasurer & Executive Vice President at Bioverativ, Inc. Mr. Greene obtained an undergraduate degree from The State University of New York and an MBA from Kellogg School of Management. |
| Harold Edward Fleming |
Harold Edward Fleming is currently an Independent Director at CRISPR Therapeutics AG, a Director at Komodo Health, Inc., and a Director-Visitors Board at Vanderbilt School of Medicine Basic Sciences. He was previously a Senior Partner at Mckinsey & Co., Inc. (California). Fleming received his undergraduate degree from Harvard University and his doctorate from Vanderbilt University. |
| Douglas A. Treco |
Douglas A. Treco is the founder of Transkaryotic Therapies, Inc., which was founded in 1988. He held the title of Senior Vice President-Research & Development from 1988 to 2005. He is also the founder of Ra Pharmaceuticals, Inc., which was founded in 2008. He served as the President & Chief Executive Officer in 2020. Currently, Dr. Treco is the Chairman & Chief Executive Officer at Inozyme Pharma, Inc. since 2023. He is also the Lead Independent Director at CRISPR Therapeutics AG since 2021. Additionally, he holds positions as a Scientific Advisor at LSV Capital Management LLC and as a Special Advisor at 3CC Management LLC. In the past, Dr. Treco served as the Chief Executive Officer & Director at Alchemab Therapeutics Ltd. from 2021 to 2022. He was also a Director at Xcellerex, Inc. Furthermore, he worked as an Entrepreneur-in-Residence at Morgenthaler Management Corp. from 2008 to 2014. Dr. Treco obtained a doctorate degree from Stony Brook University in 1984. He also holds an undergraduate degree from the University of Delaware, which he received in 1979. |
